Company Encyclopedia
View More
name
HBM HOLDINGS-B
02142.HK
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for treating myasthenia gravis; Porustobart HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 for treating melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm. It is also developing HBM7020 for treating hematologic carcinoma and autoimmune diseases; HBM9378 for the treatment of asthma and chronic obstructive pulmonary disease; and HBM1020, HBM1022, HBM9014, HBM7022, HBM7008, HBM9027, HBM7004, and HBM9033 for treating solid tumors.
1.371 T
02142.HKMarket value -Rank by Market Cap -/-

Financial Score

20/11/2025 Update
B
BiotechnologyIndustry
Industry Ranking5/52
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE36.01%A
    • Profit Margin63.15%A
    • Gross Margin95.21%A
  • Growth ScoreA
    • Revenue YoY59.68%A
    • Net Profit YoY241.86%A
    • Total Assets YoY74.08%A
    • Net Assets YoY132.13%A
  • Cash ScoreB
    • Cash Flow Margin158.36%C
    • OCF YoY59.68%A
  • Operating ScoreC
    • Turnover0.39C
  • Debt ScoreB
    • Gearing Ratio25.47%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    BUZZ-HK-listed Hbm climbs to six-week high on licence deal with Pfizer

    Hbm Holdings' shares surged 7.8% to a six-week high following a licensing deal with Pfizer. The agreement allows Pfizer global rights to Nona Biosciences' HCAb platform for antibody discovery, with Nona receiving upfront and potential milestone payments. This marks Hbm's largest intraday rise since September 30, with its stock up 676.9% year-to-date.

    Reuters·
    HK
    02142
    +2.32%
    Reuters·
    HK
    02142
    +2.32%

    HBM Holdings Repurchases 100,000 Shares at HKD 13.72 Each, Files Next Day Disclosure Return to HKEX

    HBM Holdings Ltd. repurchased 100,000 shares at HKD 13.72 each, totaling HKD 1,368,190. The shares will be held as treasury shares. The company filed a Next Day Disclosure Return with the Hong Kong Stock Exchange. The original content was published on November 18, 2025.

    Reuters·
    HK
    02142
    +2.32%
    Reuters·
    HK
    02142
    +2.32%

    HBM Holdings Files HKEX Disclosure on Repurchase of 100,000 Shares at HKD 13.8 Each

    HBM Holdings Ltd. filed a disclosure with HKEX about repurchasing 100,000 shares at HKD 13.8 each, totaling HKD 1,374,990. The shares will be held as treasury shares.

    Reuters·
    HK
    02142
    +2.32%
    Reuters·
    HK
    02142
    +2.32%

    HBM Holdings Repurchases 200,000 Shares at HKD 13.24–13.67, Files Disclosure to HKEX

    HBM Holdings Ltd. has repurchased 200,000 shares at a price range of HKD 13.24–13.67, totaling HKD 2,701,070. The company has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange, indicating that the repurchased shares will be held as treasury shares.

    Reuters·
    HK
    02142
    +2.32%
    Reuters·
    HK
    02142
    +2.32%

    HBM Holdings Files HKEX Disclosure on Buyback of 150,000 Shares at HKD 13.27 Each

    HBM Holdings Ltd. has disclosed a buyback of 150,000 shares at HKD 13.27 each, totaling HKD 1,978,020, in a Next Day Disclosure Return filed with the Hong Kong Stock Exchange. The repurchased shares will be held as treasury shares.

    Reuters·
    HK
    02142
    +2.32%
    Reuters·
    HK
    02142
    +2.32%